GlassScriptPhysician profile
Michael V Jaglal
NPI 1417024746
$105,502.53
in general payments reported to CMS, 2019-2025
19 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $13K · 2021: $1,013 · 2022: $17K · 2023: $21K · 2024: $24K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $50K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,225 · Travel and Lodging: $3,678 · Food and Beverage: $1,405 · Honoraria: $833 · Education: $6.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $49,993.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,225.00 |
| Travel and Lodging | $3,678.17 |
| Food and Beverage | $1,405.24 |
| Honoraria | $832.50 |
| Education | $6.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $27,056.05 | 2022-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $23,573.02 | 2019-2022 | |
| Genzyme Corporation | $16,340.70 | 2020-2025 | |
| Sobi, INC | $13,202.17 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $8,245.00 | 2023-2025 | |
| Pfizer INC. | $7,386.26 | 2023-2024 | |
| Agios Pharmaceuticals, INC. | $2,775.00 | 2022-2023 | Pyrukynd |
| Alnylam Pharmaceuticals INC. | $2,760.00 | 2024 | Givlaari |
| Janssen Global Services, LLC | $2,180.00 | 2023 | |
| Janssen Pharmaceuticals, INC | $1,250.00 | 2024 | Xarelto |
| Astellas Pharma US INC | $135.91 | 2019-2021 | |
| Celgene Corporation | $130.67 | 2025 | Breyanzi |
| Gt Medical Technologies, INC | $123.97 | 2025 | Gammatile |
| Abbvie INC. | $121.15 | 2021 | |
| Xeris Pharmaceuticals, INC. | $82.41 | 2023 | Gvoke Hypopen |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $76.95 | 2019 | |
| Pharmacosmos Therapeutics INC. | $39.24 | 2022 | |
| Csl Behring | $17.92 | 2024 | Hemgenix |
| Rigel Pharmaceuticals, INC. | $6.11 | 2024 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jaglal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.